Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBT: 2014-2025

Historic EBT for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$67.1 million.

  • Ascendis Pharma A's EBT rose 37.79% to -$67.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$245.1 million, marking a year-over-year increase of 45.81%. This contributed to the annual value of -$404.0 million for FY2024, which is 20.81% up from last year.
  • As of Q3 2025, Ascendis Pharma A's EBT stood at -$67.1 million, which was down 69.26% from -$39.6 million recorded in Q2 2025.
  • Ascendis Pharma A's EBT's 5-year high stood at -$39.6 million during Q2 2025, with a 5-year trough of -$206.2 million in Q4 2022.
  • For the 3-year period, Ascendis Pharma A's EBT averaged around -$102.1 million, with its median value being -$107.8 million (2024).
  • In the last 5 years, Ascendis Pharma A's EBT tumbled by 85.04% in 2022 and then skyrocketed by 66.29% in 2025.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's EBT stood at -$121.5 million in 2021, then plummeted by 69.73% to -$206.2 million in 2022, then spiked by 57.68% to -$87.2 million in 2023, then surged by 54.21% to -$39.9 million in 2024, then surged by 37.79% to -$67.1 million in 2025.
  • Its last three reported values are -$67.1 million in Q3 2025, -$39.6 million for Q2 2025, and -$98.4 million during Q1 2025.